EQT's Galderma announces positive trial results on skin drug

1 minute read

A Swiss flag is pictured on the Federal Palace (Bundeshaus) in Bern, Switzerland December 7, 2018. REUTERS/Denis Balibouse

Register now for FREE unlimited access to Reuters.com

BERLIN, June 22 (Reuters) - EQT's (EQTAB.ST) Galderma on Wednesday said its injectable drug nemolizumab helped patients suffering from the rare skin disease prurigo nodularis in a trial, potentially underpinning the owner's ambitions to list the skincare firm.

In a late-stage trial, Galderma's drug was shown to remove lesions and ease itch in some patients. Itch is a chronic symptom of the potentially debilitating skin disease.

Sources told Reuters in May that EQT is delaying listing plans for Galderma as market volatility and recession fears in Europe cool investor appetite for what could be Switzerland's biggest flotation in more than two decades. read more

The listing could happen in the autumn or early next year depending on market conditions, the sources said at the time.

Japan's Maruho Co. Ltd is also working on a prurigo nodularis treatment while French drugmaker Sanofi (SASY.PA) is running trials to get its bestselling eczema drug Dupixent also approved for the disease.

Register now for FREE unlimited access to Reuters.com
Reporting by Ludwig Burger, Writing by Miranda Murray

Our Standards: The Thomson Reuters Trust Principles.